Allopartis Acquired By Novozymes


In XSeed’s first fund, we allocated a portion of capital to entrepreneurs pursuing breakthrough innovation at the intersection of IT and other technical disciplines. Our reasoning in pursuing these and a handful of other such investments was straight- forward: We believed, given the cost-performance vector of IT, that it would rapidly transform other disciplines and that companies could be built cost-effectively at the intersection. We believed that great entrepreneurs pursuing differentiated, novel technical approaches to solve valuable problems could create unique customer value in those areas. As markets changed, we believed that such startups would retain inherent value in good economic times and bad.

With that prelude, we’re pleased to announce the acquisition of our portfolio company, Allopartis, by Danish industrial giant, Novozymes (NVZMY). All credit goes to the Allopartis team for building a screening and evolution platform with enduring value and to Novozymes for recognizing the speed advantages Allopartis will bring to its development efforts.

Congrats to Robert Blazej, Nick Toriello, Charlie Emrich, and the entire Allopartis team!